Kajian Literatur Interaksi Farmakokinetik Obat Golongan Statin dengan Golongan Antiretroviral
DOI:
https://doi.org/10.33143/jhtm.v8i2.2304Abstract
Interaksi obat adalah situasi dimana suatu zat mempengaruhi aktivitas obat, yaitu meningkatkan atau menurunkan efeknya, atau menghasilkan efek baru yang tidak diinginkan atau direncanakan. Penelitian ini bertujuan untuk mengetahui bagaimana interaksi farmakokinetik obat golongan statin dengan golongan antiretroviral.. Penelitian ini merupakan merupakan studi literature. Hasil dari penelitian ini dengan 4 artikel yang memenuhi kriteria inklusi. Berdasarkan hasil penelitian ini dapat ditarik kesimpulan bahwa obat golongan statin yang berinteraksi dengan obat antiretroviral, efek dari interaksi yang terjadi yaitu dapat terjadi peningkatan ataupun penurunan nilai AUC maupun Cmax. Adanya peningkatan kadar ini dapat menyebabkan toksisitas dan ketika terjadinya penurunan dapat mengakibatkan tidak tercapainya efek terapi, sehingga jika ingin diberikan bersamaan perlu dilakukan penyesuain dosis.
Kata Kunci: Interaksi farmakokinetik, Golongan statin, Golongan antiretroviral.
A drug interaction is a situation in which a substance affects the activity of a drug, i.e. increases or decreases its effect, or produces a new, unwanted or planned effect. This study aims to determine how the pharmacokinetic interactions of statin drugs with antiretroviral groups. This study is a literature study. The results of this study with 4 articles that meet the inclusion criteria. Based on the results of this study, it can be concluded that for statin drugs that interact with antiretroviral drugs, the effect of the interactions that occur is that there can be an increase or decrease in AUC and Cmax values. An increase in this level can cause toxicity and when a decrease occurs, it can result in not achieving the therapeutic effect, so if you want to give it simultaneously it is necessary to adjust the dose.
Keywords: Pharmacokinetic interactions, statin group, antiretroviral group.
Â
References
Aberg, J. A. (2009). Lipid Management in Patients Who Have HIV and Are Receiving HIV Therapy. Endocrinology and Metabolism Clinics of North America, 38(1), 207–222.
Anggriani, Y., Yunihastuti, E., & Dkk. (2019). Perbandingan Penggunaan Efavirenz dan Nevirapine Terhadap Kolesterol LDL Pasien HIV/AIDS. Pharmaceutical Sciences and Research, 6(2), 118–123.
Hanutami, B., & Dandan, K. L. (2019). Identifikasi Potensi Interaksi Antar Obat Pada Resep Umum Di Apotek Kimia Farma 58 Kota Bandung Bulan April 2019. Farmaka, 17(April), 57–64.
Hardianto, D. (2014). Tinjauan Lovastatin Dan Aplikasinya. Jurnal Bioteknologi & Biosains Indonesia (JBBI), 1(1), 38–44.
Kemenkes RI. (2011). Pedoman Nasional Tatalaksana Klinis Infeksi HIV dan Terapi Antiretroviral Pada Orang Dewasa. Jakarta.
Kemenkes RI. (2015). Peratuan Menteri Kesehatan RI No 87 Tahun 2014 Tentang Pedoman Pengobatan Antiretroviral. Jakarta.
Mayangsari, E., Lestari, B., & dkk. (2019). Farmakoterapi Kardiovaskular. UB Press
Puspasari, D., Wisaksana, R., & Dkk. (2018). Gambaran Efek Samping dan Kepatuhan Terapi Antiretroviral pada Pasien HIV di Rumah Sakit Dr. Hasan Sadikin Bandung tahun 2015. Jurnal Sistem Kesehatan, 3(4), 175–181.
Rakhmanina, N. Y., & van den Anker, J. N. (2010). Efavirenz in the therapy of HIV infection. Expert Opinion on Drug Metabolism & Toxicology, 6(1), 95–103.
RI, D. (2006). Pedoman Nasional Tatalaksana Klinis Infeksi HIV dan Terapi Antiretroviral.
Riry & Armen. (2018). Human Immunodeficiency Virus-Acquired Immunodeficiency Syndrome dengan arkoma Kaposi. Jurnal Kesehatan Andalas, 7.
Sentral, O., Kadar, D. A. N., & Darah, K. (2013). Obesitas Sentral Dan Kadar Kolesterol Darah Total. KESMAS - Jurnal Kesehatan Masyarakat, 9(1), 37–43.
Soegeng Soegijanto. (2016). Penyakit Tropis dan Infeksi di Indonesia. Surabaya
Yoviana S. (2012). Kolesterol. Yogyakarta : Pinang Merah Publisher.
Zamzami, A. J., Waluya, S. B., & dkk. (2018). Pemodelan Matematika dan Analisis Kestabilan Model Penyebaran HIV / AIDS Dengan Treatment. Unnes Journal of Mathematics, 7(2), 142–154.
Poe Hirr Hsyu, Melissa D., & dkk. (2001). Pharmacocinetic Interactions between Nelfinavir and 3- Hydroxy-3- Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Simvastatin. American Society for Microbiology , 45 (12), 45-50.
J Acquir Immune Defic Syndr., & dkk. (2014). Lack of Pharmacokinetic Interactions Between Pitavastatin and Efavirenz or Darunavir/Ritonavir. Hhs Public Access Authors manuscript. 1-16.
John G. Gerber., & dkk. (2005). Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastati, and Pravastatin. Results of AIDS Clinical Trials Group 5108 Study, 39 (3),307-312.
Niresh Hariparsad., & dkk. (2004). Induction of CYP3A4 by Efavirenz in Primary Human Hepatocytes : Comparison With Rifampin and Phenobarbital. The Journal of Clinical Pharmacology, 44 (11), 73-81.
Marika T Granfors., & dkk. (2006). Diffrential Inhibition of Cytochrome P450 3A4, 3A5 and 3A7 by Five Human Immunodeficiency Virus (HIV) Protease Inhibitors in Vitro. Basic Clinical Pharmacol Toxicol.
Downloads
Issue
Section
License
I. ORIGINALITY, AUTHORSHIP, AND COPYRIGHT
The manuscripts submitted for publication must be research works written in English that have not been previously published and  are not being considered for publication elsewhere. All the authors must have agreed to the submission and to the order of their names on the title page. They must also have agreed that the corresponding author may act on their behalf throughout the editorial review and publication process. The corresponding author is responsible for obtaining such agreement.
Requests for changes in authorship (order of listing or addition or deletion of names) after submission should be accompanied by signed statements of agreement from all the parties involved. To maintain and protect the publisher‘s ownership and rights and to protect the original authors from misappropriations of their published work, author(s) are required to sign a Journal Publishing Agreement and send it to the editorial office (jhtm@uui.ac.id).
II. PERMISSION
The author is responsible for acquiring the permission(s) to reproduce any copyrighted figures, tables, data, or text that are being used in the submitted paper. Authors should note that text quotations of more than 250 words from a published or copyrighted work will require grant of permission from the original publisher to reprint. The written permission letter(s) must be submitted together with the manuscript.
III. EDITORIAL REVIEW AND REVISION
All papers will be critically read by at least two anonymous reviewers, selected for their competence in the subject area of the paper. Acceptance of the paper will depend upon its scientific merit and suitability for the journal. A paper may be accepted in its original form or subject to revision.
The reviewers' (and editor's) suggestions will be conveyed to the author, who will then have an opportunity to revise the paper. A manuscript returned to an author for revision can be held for a maximum of eight weeks.
The accepted paper will be edited by native English speakers. The cost of language editing service is currently free.
IV. PROOFS
Galley proofs (PDF format) for an accepted article will be sent by e-mail to the corresponding author for copyediting corrections. The core content of an article cannot be changed at this time. It is the author's responsibility to check the entire manuscript, including tables, figure legends, and cited reference numbers, not just the items queried. The proofs should be corrected and mailed to the editorial office within 48 hours of receipt in order to expedite publication. Only one set of corrections will be accepted. In other words, it is important to ensure that all of your corrections are sent to us in one communication.
V. Â REPRINTS
Five free reprint copies of the published article will be shipped to the corresponding authors in Indonesia only, approximately two weeks after the issue is printed. Authors, including overseas authors, who wish to purchase reprints, are required to complete the Reprint Order Form, which will be sent with the galley proofs to corresponding authors. This form must be returned together with the corrected galley proofs.
